drugset / Trial / NCT04201873
Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma
Phase 1
Active not recruiting
40 enrolled
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC · collabNational Cancer Institute (NCI) · collabOncovir, Inc. · collabPhase One Foundation · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This phase I trial studies the side effects and how well of pembrolizumab and a vaccine therapy (ATL-DC vaccine) work in treating patients with glioblastoma that has come back (recurrent) and can be removed by surgery (surgically accessible). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Vaccines, such as ATL-DC vaccine, may help the body build an effective immune response to kill tumor cells. Giving pembrolizumab and ATL-DC vaccine may work better in treating patients with glioblastoma compared to ATL-DC alone.
Timeline
- Start
- 2020-01-08
- Primary completion
- 2026-08-01
- Completion
- 2027-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dendritic Cell Tumor Cell Lysate Vaccine | Vaccine | — | Intrathecal |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Background | Hiltonol | Other / unclassified | — | Intramuscular |